Open AccessS212: PHASE I STUDY OF YTB323, A CHIMERIC ANTIGEN RECEPTOR (CAR)‐T CELL THERAPY MANUFACTURED USING T‐CHARGE™, IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
Author(s) -
Dickinson M.,
Kwon M.,
Briones J.,
Jäger U.,
Kato K.,
Bachy E.,
Blaise D.,
Boissel N.,
Shah N.,
Frigault M,
Riedell P.,
Shune L.,
Teshima T.,
Zhu X.,
Orlando E.,
Yi L.,
Davis J.,
Bleickardt E.,
Flinn I.,
Barba P.,
Barba P.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843740.59934.f7
Subject(s) - medicine , chimeric antigen receptor , diffuse large b cell lymphoma , refractory (planetary science) , lymphoma , phases of clinical research , oncology , cd19 , t cell , clinical trial , antigen , immunology , immunotherapy , cancer , immune system , biology , astrobiology